The RVNC news page on Stock Titan provides an archive of announcements and transaction-related communications concerning Revance Therapeutics, Inc., a biotechnology company focused on aesthetic and therapeutic offerings. These news items document Revance’s role in the aesthetic injectables market, its product portfolio, and the corporate events that led to its acquisition by Crown Laboratories, Inc.
Readers can review press releases describing Crown’s commencement of a cash tender offer to acquire all outstanding shares of Revance, subsequent extensions of the tender offer, and an increase in the offer price that was unanimously approved by the Revance Board of Directors. Additional news items cover competing interest from Teoxane SA, reminders to Revance stockholders about tendering their shares, and joint announcements by Crown and Revance regarding the expiration of the tender offer and satisfaction of its conditions.
The archive also includes Crown’s announcements of the successful closing of the acquisition and completion of the second-step merger, in which Crown stated that Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered. These releases provide context on how Revance, as the issuer of RVNC, transitioned from an independent publicly traded biotechnology company to a Crown-owned business within a larger skincare and aesthetics platform.
For investors and researchers, the RVNC news feed serves as a historical record of key milestones, including strategic reviews by the Revance Board, tender offer mechanics, and the ultimate outcome of the Crown transaction. Users interested in the evolution of Revance’s aesthetic and therapeutic portfolio, its partnerships with Teoxane SA, Viatris Inc., and Shanghai Fosun Pharmaceutical, and the terms of the acquisition can use this page to trace the sequence of public communications around the deal.
Revance Therapeutics will release its Q4 and full year 2021 financial results on February 28, 2022 after market close. A conference call and live webcast will occur at 4:30 p.m. ET to discuss results and provide a business update. Revance is focused on innovative aesthetic and therapeutic products with a strong pipeline, including DaxibotulinumtoxinA, currently seeking U.S. regulatory approval for glabellar lines and cervical dystonia. They also hold exclusive U.S. rights to the RHA® Collection of dermal fillers.
Revance Therapeutics (NASDAQ: RVNC) announced that it received Type A meeting minutes from the FDA concerning the Complete Response Letter (CRL) for DaxibotulinumtoxinA for Injection. A requalification of the new working cell bank (WCB) is required, which involves producing three drug substance lots and one drug product lot. The FDA mandates a reinspection of Revance’s facility once the resubmission is accepted, which could take up to 6 months. The CEO expressed confidence in a clear path for BLA resubmission.
Revance Therapeutics (RVNC) reported preliminary Q4 2021 RHA® Collection revenue between $23.0 million and $24.0 million, bringing full-year revenue to approximately $70.0 million to $71.0 million. Cash, cash equivalents, and short-term investments stood at about $225 million as of December 31. The company expects its operating expenses for the year to be at the lower end or below earlier guidance of $375 million to $390 million. Revance held a Type A meeting with the FDA regarding DaxibotulinumtoxinA for Injection.
Revance Therapeutics (NASDAQ: RVNC) presented new data on DaxibotulinumtoxinA for Injection at the ASDS Virtual Annual Meeting from November 19-21, 2021. Highlights include findings from the SAKURA Phase 3 trials, which assessed immunogenicity and treatment for glabellar lines. An innovative injection technique for midface volumization using hyaluronic acid fillers was also discussed. The presentations underscore Revance's commitment to setting new standards in facial aesthetics and its robust growth pipeline.
Revance Therapeutics (NASDAQ: RVNC) announces CEO Mark Foley and CFO Tobin Schilke will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. This event will stream online starting November 22 in the investor relations section of Revance’s website. The conference runs from November 30 to December 2, 2021. Revance focuses on innovative aesthetic and therapeutic solutions, including DaxibotulinumtoxinA for Injection, which is seeking U.S. regulatory approval after completing Phase 3 trials.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17. CEO Mark Foley is set to present on November 17 at 8:20 a.m. CT. Interested parties can access the live audio webcast via the company's Investor Relations page. Revance specializes in innovative aesthetic and therapeutic products, including its neuromodulator DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials for glabellar lines and is pursuing U.S. regulatory approval.
Revance Therapeutics (RVNC) reported Q3 2021 revenue of $19.7 million, a substantial increase from $3.8 million in Q3 2020, primarily driven by the RHA® Collection of dermal fillers, which generated $18.3 million this quarter. The net loss decreased to $74.4 million from $81.3 million year-over-year. The company plans to request a Type A meeting with the FDA to address deficiencies in its BLA for DaxibotulinumtoxinA for Injection for glabellar lines. Additionally, positive results from the ASPEN-OLS Phase 3 study for cervical dystonia were announced, showing the product's long-term safety and effectiveness.
Revance Therapeutics, Inc. (NASDAQ: RVNC) will announce its third quarter 2021 financial results on November 9, 2021, after market close. A conference call and live webcast will occur at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and offer a business and pipeline update. Revance focuses on innovative aesthetic and therapeutic products, including the next-generation neuromodulator DaxibotulinumtoxinA for Injection, aiming for U.S. regulatory approval. The company also partners with Viatris to develop a biosimilar to BOTOX®.
Revance Therapeutics (NASDAQ: RVNC) announced a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection, intended for treating moderate to severe glabellar lines. Received on October 15, the CRL indicates deficiencies found during the FDA's inspection of Revance's manufacturing facility. Revance plans to request a Type A meeting with the FDA to address these issues. CEO Mark Foley expressed disappointment at this unexpected response but reiterated the company's commitment to launching their neuromodulator product.
Revance Therapeutics (NASDAQ: RVNC) announces that its Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under FDA review. The company anticipates FDA approval for treating glabellar lines in 2021. While the issuance of a Form 483 is common post-inspection, Revance confidently submitted a response in July 2021. The innovative neuromodulator product DaxibotulinumtoxinA features a proprietary stabilizing peptide excipient, enhancing its market potential.